APIMEDS PHARMACEUTICALS US I (APUS) Stock Overview
USA - NYSEARCA:APUS - US03771D1028 - Common Stock
APUS Key Statistics, Chart & Performance
The current stock price of APUS is 1.84 USD. In the past month the price decreased by -8.91%.
APUS Latest News, Press Relases and Analysis
APUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.55B | ||
| AMGN | AMGEN INC | 13.7 | 160.87B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
| ARGX | ARGENX SE - ADR | 91.6 | 51.94B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 8.93 | 20.97B |
Related stock screener links
About APUS
Company Profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Company Info
APIMEDS PHARMACEUTICALS US I
100 Matawan Road, Suite 325
Matawan NEW JERSEY US
Employees: 2
Phone: 18482015010
APIMEDS PHARMACEUTICALS US I / APUS FAQ
What is the stock price of APIMEDS PHARMACEUTICALS US I today?
The current stock price of APUS is 1.84 USD.
What is the ticker symbol for APIMEDS PHARMACEUTICALS US I stock?
The exchange symbol of APIMEDS PHARMACEUTICALS US I is APUS and it is listed on the NYSE Arca exchange.
On which exchange is APUS stock listed?
APUS stock is listed on the NYSE Arca exchange.
What is APIMEDS PHARMACEUTICALS US I worth?
APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 23.15M USD. This makes APUS a Nano Cap stock.
How many employees does APIMEDS PHARMACEUTICALS US I have?
APIMEDS PHARMACEUTICALS US I (APUS) currently has 2 employees.
What are the support and resistance levels for APIMEDS PHARMACEUTICALS US I (APUS) stock?
APIMEDS PHARMACEUTICALS US I (APUS) has a support level at 1.84 and a resistance level at 2.09. Check the full technical report for a detailed analysis of APUS support and resistance levels.
Should I buy APIMEDS PHARMACEUTICALS US I (APUS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APUS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APUS, evaluating the profitability, health, valuation and growth aspects
- APIMEDS PHARMACEUTICALS US I (APUS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APIMEDS PHARMACEUTICALS US I (APUS) Sales and EPS estimates to see what analysts future expectations are.
- APIMEDS PHARMACEUTICALS US I (APUS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APIMEDS PHARMACEUTICALS US I (APUS) Insider and Institutional Ownership to learn about the owners and their transactions.
- APIMEDS PHARMACEUTICALS US I (APUS) Stock Chart to make your own analysis
- APIMEDS PHARMACEUTICALS US I (APUS) Latest news and press-releases to stay up to date.
Does APIMEDS PHARMACEUTICALS US I (APUS) stock pay dividends?
APUS does not pay a dividend.
What is the Price/Earnings (PE) ratio of APIMEDS PHARMACEUTICALS US I (APUS)?
APIMEDS PHARMACEUTICALS US I (APUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
What is the Short Interest ratio of APIMEDS PHARMACEUTICALS US I (APUS) stock?
The outstanding short interest for APIMEDS PHARMACEUTICALS US I (APUS) is 3.28% of its float. Check the ownership tab for more information on the APUS short interest.
APUS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to APUS.
APUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APUS. While APUS has a great health rating, there are worries on its profitability.
APUS Financial Highlights
Over the last trailing twelve months APUS reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -78.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.18% | ||
| ROE | -14.27% | ||
| Debt/Equity | 0 |